Single-cell map of GRN-related frontotemporal dementia and related Alzheimer's changes

Single Cell Characterization of FTLD-GRN

NIH-funded research University of California, San Francisco · NIH-10700363

Researchers are using single-cell methods to pinpoint how low Progranulin from GRN gene changes harms brain immune cells and neurons in people with GRN-linked frontotemporal dementia and some Alzheimer's cases.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Francisco NIH-funded
Lab location1 site (San Francisco, United States)
Project IDNIH-10700363 on NIH RePORTER

What this research studies

This project will profile individual brain nuclei from mouse models and donated human frontal cortex and thalamus using single-nucleus RNA sequencing and chromatin-accessibility assays to see which cell types change when Progranulin (PGRN) is low. If you or a loved one has a GRN mutation or frontotemporal dementia, the team will compare your tissue to controls to link genetics to cell-level inflammation and TDP-43 protein clumps. The researchers focus on microglia (brain immune cells) that lose normal genes and become pro-inflammatory and on neurons that show TDP-43 pathology and degeneration. The goal is to identify specific cell pathways and biomarkers that could guide future targeted therapies.

Who could benefit from this research

Good fit: Ideal candidates include people with known GRN mutations, a clinical diagnosis of frontotemporal dementia, or Alzheimer's patients with suspected TDP-43 involvement who can donate brain tissue or provide related biospecimens.

Not a fit: Patients with dementias caused by unrelated mechanisms or without GRN/TDP-43 involvement may not receive direct benefit from this work.

Why it matters

Potential benefit: Could identify the precise cell types and molecular pathways driving neurodegeneration in GRN-related FTLD and some Alzheimer’s cases, pointing to targets or biomarkers for future treatments.

How similar studies have performed: Prior mouse models and small human postmortem single-cell studies—including the team's pilot data—have shown microglial activation and links to TDP-43, so this builds on promising but still early evidence.

Where this research is happening

San Francisco, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorder
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.